Anti-AAV9 Antibodies and ELISA Kits Complete Resource for AAV9 Detection and Quantification

Adeno-associated virus serotype nine (AAV9) has emerged as one of the most exciting and versatile vectors in the field of gene therapy, distinguished by its unique ability to cross the blood-brain barrier and transduce cells throughout the central nervous system following systemic administration. This remarkable property sets AAV9 apart from all other naturally occurring AAV serotypes and has opened new possibilities for treating neurological disorders that were previously considered inaccessible to gene therapy. Beyond its central nervous system tropism, AAV9 also efficiently transduces a wide range of peripheral tissues including cardiac muscle, skeletal muscle, and liver, making it a truly multi-tropic vector suitable for diverse therapeutic applications.Despite its many advantages, the successful development and clinical translation of AAV9-based gene therapies depend critically on accurate monitoring of host immune responses against the vector. Preexisting neutralizing antibodies and treatment-emergent anti-AAV9 antibodies can significantly reduce transduction efficiency, limit therapeutic efficacy, and pose patient safety risks. Reliable serological detection of anti-AAV9 antibodies is therefore essential for patient screening, dose stratification, and post-treatment monitoring. This page provides a comprehensive overview of AAV9 biology, its unique properties and applications in gene therapy, and validated detection solutions including human and mouse anti-AAV9 antibody ELISA kits.

Figure 1.Anti-AAV9 Antibodies and ELISA Kits Complete Resource for AAV9 Detection and Quantification.

Capsid Structure and Receptor Binding

The AAV9 capsid adopts the characteristic icosahedral architecture common to all AAV serotypes. The capsid is assembled from sixty copies of the three viral proteins VP1, VP2, and VP3, which share a common carboxy-terminal region but differ at their amino-termini. The VP1 unique region contains a phospholipase A2 domain essential for endosomal escape, while VP3 forms the core structural scaffold of the capsid. The primary cellular receptor for AAV9 is the universal receptor AAVR, a transmembrane protein expressed on the surface of many cell types across multiple species. The interaction between AAV9 and AAVR is mediated by specific amino acid residues on the capsid surface that form a binding pocket complementary to the receptor structure. This interaction is species-conserved, explaining the ability of AAV9 to transduce cells from humans, mice, non-human primates, and other species with high efficiency. In addition to AAVR, AAV9 utilizes a variety of co-receptors and alternative receptors that contribute to its broad tropism. Terminal galactose residues on cell surface glycoproteins have been identified as important binding determinants for AAV9, and the presence of these glycans on brain endothelial cells may facilitate blood-brain barrier crossing. The multifactorial receptor engagement strategy of AAV9 enables robust transduction across diverse tissue types and species.

Clinical Applications

Product Overview Human Anti-AAV9 Antibody ELISA Kit

The Human Anti-AAV9 Antibody ELISA Kit is designed for the quantitative or qualitative determination of total anti-AAV9 antibodies in human serum, plasma, or other biological fluids. This kit is optimized for high-throughput screening applications in clinical research and regulatory-compliant environments.

Key Features

• High Sensitivity: Detects anti-AAV9 antibodies at very low concentrations, ensuring reliable identification of low-titer seropositive samples that may be missed by less sensitive methods.
• Broad Dynamic Range: Accommodates both seronegative and high-titer samples without the need for extensive dilution optimization.
• Specificity Verified: Distinguishes anti-AAV9 antibodies from antibodies against other AAV serotypes, enabling accurate serotyping of patient samples.
• Ready-to-Use Format: Pre-coated plates with purified intact AAV9 particles, pre-diluted standards, and concentrated reagents reduce hands-on time and minimize operator error.
• Qualitative and Quantitative Options: Can be used for binary patient screening or absolute quantification of antibody concentrations using a standard curve.

Conclusions

AAV9 holds a unique and powerful position in the field of gene therapy, distinguished by its unparalleled ability to cross the blood-brain barrier and transduce cells throughout the central nervous system following systemic administration. This remarkable property, combined with efficient transduction of cardiac muscle, skeletal muscle, and liver, makes AAV9 an extraordinarily versatile vector applicable to a wide range of therapeutic indications. The successful clinical development of AAV9-based therapies for spinal muscular atrophy has transformed the treatment landscape for this devastating disorder and validated the clinical potential of systemic AAV9 delivery. However, the prevalence of preexisting neutralizing antibodies and the potential for treatment-emergent immune responses pose significant challenges to the successful clinical application of AAV9-based therapeutics. The Human Anti-AAV9 Antibody ELISA Kit and Mouse Anti-AAV9 Antibody ELISA Kit provide validated, ready-to-use solutions for serological screening and immunogenicity monitoring, offering high sensitivity, specificity, and reproducibility.